Article
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Minerva medica - 1 Oct 2020
Abdul-Hamil Nurul A, Wong Gee C, Nagarajan Chandramouli, Martinelli Giovanni, Cherchione Claudio
Abstract excerpt
Mutation within the FMS-like tyrosine kinase 3 (FLT3) gene are one of the most frequent genetic alterations in acute myeloid leukemia. A high mutation fraction of FLT3-ITD molecules on the surface of leukemia cells is associated with short remissions and overall adverse outcomes in AML. In this a...
Topics
- Aniline Compounds
- Anthracyclines
- Antifungal Agents
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Trials as Topic
- Cytarabine
- Cytochrome P-450 CYP3A Inhibitors
- Drug Interactions
- Echinocandins
- Forecasting
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
- Maintenance Chemotherapy
- Mutation
- Mycoses
- Protein Kinase Inhibitors